Evogene to Present at the 24th Schrödinger European User Group Meeting

Rhea-AI Summary

Evogene (NASDAQ:EVGN), a computational chemistry company focused on generative AI design of small molecules for pharma and agriculture, will present at the 24th Schrödinger European User Group Meeting in Munich, Germany, held May 19–21, 2026.

Head of Algorithms Dr. Roberto Olender will speak in the Small Molecules track session “Project Advancements Through Custom Computational Models” on May 20, 2026, 11:00 AM–12:30 PM CEST, sharing progress on a multi-objective GenAI foundation model for de novo molecule design.

AI-generated analysis. Not financial advice.

News Market Reaction – EVGN

-2.05%

1 alert

-2.05% News Effect

On the day this news was published, EVGN declined 2.05%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: May 19–21, 2026 Session date: Wednesday, May 20, 2026 Session time: 11:00 AM–12:30 PM CEST +1 more

4 metrics

Conference dates May 19–21, 2026 24th Schrödinger European User Group Meeting in Munich

Session date Wednesday, May 20, 2026 Evogene presentation session schedule

Session time 11:00 AM–12:30 PM CEST Evogene’s scheduled presentation slot

Meeting edition 24th 24th Schrödinger European User Group Meeting

Market Reality Check

Price: $0.7610 Vol: Volume 85,444 is 64% abov...

high vol

$0.7610 Last Close

Volume Volume 85,444 is 64% above the 20-day average of 52,094, indicating elevated interest ahead of this conference update. high

Technical Shares at $0.7769 are trading below the $1.06 200-day moving average and 67.9% under the 52-week high.

Peers on Argus

EVGN is up 3.35% while close peers show mixed moves: LYRA and MBRX are up, where...

1 Up 1 Down

EVGN is up 3.35% while close peers show mixed moves: LYRA and MBRX are up, whereas ERNA, KZIA, and MBIO are down. Momentum scanner flags MBIO down and BRTX up, reinforcing a stock-specific rather than broad biotech move.

Historical Context

5 past events · Latest: May 07 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 07	Earnings timing	Neutral	-1.3%	Announcement of upcoming Q1 2026 results release and conference call schedule.
Apr 02	Nasdaq notice	Negative	-0.4%	Nasdaq minimum bid price noncompliance notice and defined cure period to regain listing.
Mar 31	Subsidiary field trials	Positive	+4.8%	Casterra’s successful commercial castor field trials in Brazil for biofuel feedstock.
Mar 09	Conference presentation	Neutral	-0.4%	BIO-Europe Spring 2026 presentation on AI-driven small-molecule discovery.
Mar 05	Earnings results	Negative	-6.2%	2025 results showing operating and net losses plus restructuring and asset sales.

Pattern Detected

Recent history shows negative/financially cautious headlines have aligned with downside moves, while clearly positive operational news, like successful field trials, aligned with gains. Neutral conference-related items have seen only modest reactions.

Recent Company History

Over the last six months, Evogene’s news flow mixed operational progress with financial and listing risks. A March 31 update on Casterra’s successful Brazil field trials coincided with a 4.79% gain, while the April 2 Nasdaq minimum bid notice and the March 5 2025 results (including losses and restructuring) saw declines of 0.41% and 6.16%. Conference announcements on March 9 and the May 7 Q1 2026 scheduling produced only small moves, framing today’s user group presentation as part of a broader outreach and partnering narrative.

Regulatory & Risk Context

Active S-3 Shelf · $6.35 million

Shelf Active

Active S-3 Shelf Registration 2026-03-26

$6.35 million registered capacity

An effective F-3 shelf dated March 26, 2026 registers 5,076,924 shares tied to warrants, with potential proceeds of $6.35 million to Evogene if exercised for cash; resales are by a selling shareholder and do not provide additional funds.

Market Pulse Summary

This announcement highlights Evogene’s participation in a major user group meeting, underscoring its...

Analysis

This announcement highlights Evogene’s participation in a major user group meeting, underscoring its focus on generative AI and computational drug discovery for small molecules. Recent history mixes operational progress, like Casterra’s Brazilian field trials, with financial strain and Nasdaq minimum bid price issues. Investors may watch how such conferences translate into partnerships or funding, especially given the effective F-3 for 5,076,924 warrant-linked shares and prior going‑concern disclosures.

Key Terms

computational drug discovery, generative ai, small molecules, de novo design of molecules

4 terms

computational drug discovery medical

"experts to share advances and real-world applications in computational drug discovery, Evogene has"

Computational drug discovery uses computer models, simulations and large datasets to find and test potential drug candidates before they reach a physical lab. Like using a detailed digital map and flight simulator to plot and test routes instead of trial-and-error driving, it can speed up research, cut costs and reduce early-stage failures, so investors can gauge how quickly and cheaply a drug program might advance and how much technical risk remains.

generative ai technical

"specializing in the generative AI design of small molecules for the pharmaceutical"

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

small molecules medical

"generative AI design of small molecules for the pharmaceutical and agricultural"

Small molecules are compact chemical compounds, often developed as medicines, that act by fitting into and altering the behavior of biological targets like proteins — think of them as tiny keys designed to turn specific locks in the body. For investors, they matter because small-molecule drugs are usually easier and cheaper to make, store and deliver (often as pills), have well-established regulatory pathways, and can offer scalable, potentially high-return commercial opportunities if they gain approval and market acceptance.

de novo design of molecules technical

"Multi-objective GenAI Foundation Model for De Novo Design of Molecules | Dr."

De novo design of molecules is the process of creating entirely new chemical structures from scratch to achieve a desired biological effect, rather than modifying existing drugs. For investors it matters because successful de novo designs can produce first-in-class medicines with strong patent protection and high return potential, but they also carry greater scientific and regulatory risk compared with repurposing known compounds—think inventing a new car model versus upgrading an old one.

AI-generated analysis. Not financial advice.

Conference will be held in Munich, Germany - May 19-21, 2026

REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in the 24^th Schrödinger European User Group Meeting, taking place May 19–21, 2026, in Munich, Germany.

Bringing together industry and academic experts to share advances and real-world applications in computational drug discovery, Evogene has been chosen to present its recent progress in generative design of novel compounds. Dr. Roberto Olender, Evogene's Head of Algorithms, will participate in a dedicated session on "Project advancements through custom computational models", along with presenters from other global leaders in the field. Evogene welcomes the opportunity to connect with collaborators, researchers, and industry partners to explore new avenues for advancing innovation in drug discovery.

Session Details

Track: Small Molecules
Session: Project Advancements Through Custom Computational Models

• Small Molecule Drug Design Supported by Generative Artificial Intelligence Technologies | Christoph Grebner, Sanofi
• Multi-objective GenAI Foundation Model for De Novo Design of Molecules | Dr. Roberto Olender, Evogene

Wednesday, May 20, 2026 | 11:00 AM - 12:30 PM CEST

About Evogene Ltd.: 

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.

At the core of its technology is ChemPass AI^TM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com.

Forward-Looking Statements:

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries use forward-looking statements in this press release when they discuss Evogene's progress in generative design of novel compounds. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Contact
ir@evogene.com
Tel: +972-8-9311901

Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg 

View original content:https://www.prnewswire.com/news-releases/evogene-to-present-at-the-24th-schrodinger-european-user-group-meeting-302769386.html

SOURCE Evogene

FAQ

What is Evogene (EVGN) presenting at the 24th Schrödinger European User Group Meeting in May 2026?

Evogene is presenting its multi-objective GenAI foundation model for de novo design of molecules. According to Evogene, this work highlights generative AI support for small molecule drug design in the Small Molecules track session on custom computational models.

When and where will Evogene (EVGN) present at the 24th Schrödinger European User Group Meeting?

Evogene will present in Munich, Germany, during the 24th Schrödinger European User Group Meeting, held May 19–21, 2026. According to Evogene, Dr. Roberto Olender’s session runs on Wednesday, May 20, 2026, from 11:00 AM to 12:30 PM CEST.

Who will represent Evogene (EVGN) at the 24th Schrödinger European User Group Meeting?

Evogene will be represented by Dr. Roberto Olender, its Head of Algorithms. According to Evogene, he will speak in the Small Molecules track session “Project Advancements Through Custom Computational Models” about generative AI-based small molecule design.

What is the focus of Evogene’s generative AI presentation for EVGN investors to know about?

The focus is a multi-objective GenAI foundation model for de novo molecular design. According to Evogene, this approach supports small molecule drug design by using custom computational models within the Small Molecules track session in Munich.

How does Evogene’s participation in the Schrödinger User Group Meeting relate to EVGN’s drug discovery work?

Evogene’s participation showcases advances in computational drug discovery using generative AI for small molecules. According to Evogene, presenting alongside global leaders helps demonstrate its technology’s role in designing novel compounds for pharmaceutical applications.

What session details are relevant for following Evogene (EVGN) at the Munich Schrödinger meeting?

Evogene appears in the Small Molecules track, session “Project Advancements Through Custom Computational Models.” According to Evogene, its talk, alongside other presenters, is scheduled for Wednesday, May 20, 2026, from 11:00 AM to 12:30 PM CEST.